Navigation Links
Lilly Announces Leadership Changes
Date:3/2/2009

Alex M. Azar II Makes Strategic Move to Lead Lilly USA Business-to-Business Organization and Oversee Sales and Marketing in Puerto Rico

Jack Bailey's Leadership Role Expands to Include Lilly USA Diabetes Business Unit

INDIANAPOLIS, March 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that Alex M. Azar II, currently senior vice president of corporate affairs and communications, will assume the top leadership role in Lilly's U.S. Business-to-Business organization. As vice president of Business-to-Business and Puerto Rico, Azar will oversee the company's public payer, managed care and wholesaler operations in the United States as well as oversee Lilly's sales and marketing operations in Puerto Rico.

"Lilly has been focusing for some time on advancing our understanding of and addressing, in more meaningful ways, the needs of our public and private payer customers. Given the current and unprecedented political forces on the U.S. healthcare system, this move will enable us to bring a more exclusive focus on these vital customers," said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. "Alex's strong political and healthcare background and expertise will enable us to further build the strength of the organization at a critical time for both Lilly and the industry. Additionally, this move creates a tremendous opportunity for one of our most qualified and strongest leaders to build front-line business experience at the company's largest affiliate."

In a related move, Jack Bailey, U.S. senior vice president of account-based markets, will broaden his leadership responsibilities to include oversight of the U.S. diabetes business unit. This adds to his current responsibilities for Lilly USA's oncology and cardiovascular teams, as well as the Lilly Hospi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- A modified ... help fight brain tumors, preliminary research suggests. ... investigational therapy, known as PVSRIPO, uses an engineered ... normal cells, but attacks cancer cells. The therapy ... most common and aggressive brain tumor, they said. ...
(Date:5/23/2013)... when a woman harried by hot flashes says she,s ... published online in Menopause , the journal of ... objective tests that what these women say about their ... showed that hot flashes were related to memory problems, ... there was a relationship between hot flashes and what ...
(Date:5/23/2013)... Williamsport, PA (PRWEB) May 23, 2013 ... Sitter® Teaching Site, offering a comprehensive babysitting training course ... nationally-recognized program was developed by Indianapolis pediatrician Dr. Patricia ... in the care of an adult sitter who didn’t ... a well-rounded youth development program with a medical basis ...
(Date:5/23/2013)... drug about to be tested in a clinical trial ... treatment for Alzheimer,s disease has failed to work with ... patients, according to results of a study by University ... of neuroscience affiliated with the Evelyn F. and William ... emphasized the importance of verifying promising research results before ...
(Date:5/23/2013)... 2013 The Rottenstein Law Group LLP, ... created the Tylenol Lawsuit Information Center at http://www.rotlaw.com/tylenol ... and those who are considering filing lawsuits. , ... cause severe liver damage, according to a 2009 report ... the “safety communication,” the FDA warned consumers against using ...
Breaking Medicine News(10 mins):Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Rottenstein Law Group LLP Now Accepting Tylenol Cases, Announces New Tylenol Lawsuit Information Center 2
... School of Medicine have identified proteins in the rod and ... of the genetic causes of a host of inherited ... of what goes wrong at the most basic level in ... ,Specifically, they have identified and measured the types and amounts ...
... established a Scientific Advisory Board for its transplantation ... of its United States (U.S.) clinical development ... and Larry Chodoff LifeCycle Pharma A/S OMX:LCP) today ... Board (SAB) of experts in the field of ...
... Autistic children are invariably heavier than others. Researchers ... for Disease Control and Prevention and the Cincinnati ... be contributing to such a phenomenon. ,Other studies ... rapid head growth in early life. ,However, ...
... women graduating as doctors from Medical school than men. In a ... that 58% of doctors graduating from UK medical schools in ... pursuing a career as a doctor outnumber men by almost three ... five female doctors anticipate working part-time for most of their career. ...
... There were a lot of red faces among Texan lawmakers ... twice honored as the "doctor of the day," was ... with a 17-year-old. ,The "doctor of the day" is ... public with medical needs. ,Dr. Nilon Tallant, 75, ...
... Rutgers University study has claimed that being employed on ... cause both depression and anxiety. ,According toChester ... School of Business-Camden, the lunar settlements of tomorrow - ... - carry long-term implications for the mental health of ...
Cached Medicine News:Health News:Genetic Cause of Inherited Eye Diseases Identified 2Health News:LifeCycle Pharma Forms Scientific Advisory Board in Solid Organ Transplantation 2Health News:Autism Could Be Related to Higher Level of Growth Hormones 2Health News:More Women Medical Graduates Than Men 2Health News:Sex Offender Honored Twice by Texan Lawmakers 2
(Date:5/23/2013)... -- BioElectronics Corporation (OTC Pink: BIEL), the maker of very ... panel meeting for non-thermal shortwave diathermy: The ... Meeting was held on May 21, 2013 in ... the meeting was very narrow, in that the FDA ... application of non-thermal shortwave diathermy for the treatment of ...
(Date:5/23/2013)... May 23, 2013 Halozyme Therapeutics, Inc. ... appointment of David A. Ramsay ... most recently Vice President, Corporate Development at Halozyme. ... "With his established financial management experience and ... working in our commercial group for the last ...
(Date:5/23/2013)... CARLSBAD, Calif. , May 23, 2013 Isis ... antisense therapeutics, today announced that management will present a company ... Health Care Conference on Thursday, May 30, 2013 at 8:40 ... A live audio webcast of the presentation will be ... Web site, www.isispharm.com .  A replay will be available ...
Breaking Medicine Technology:BioElectronics and Pulsed Shortwave Therapy Make Progress 2Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer 2Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2
... Resources, one of the world,s leading research and ... that the increased generic erosion of key drugs ... (Abbott/Sanofi-Aventis,s Depakote/Abbott,s Depakote ER, generics), combined with projected ... will cause a precipitous $2.3 billion decline in ...
... Aug. 25 Actelion Pharmaceuticals US, Inc., today ... (FDA) has approved the brand name VELETRI® for the ... available since April 2010 as Epoprostenol for Injection for ... (PAH) and PAH associated with the scleroderma spectrum of ...
Cached Medicine Technology:Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 2Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 3Actelion Pharmaceuticals Announces FDA Approval of Brand Name for Commercially Available VELETRI® (epoprostenol for injection) for Pulmonary Arterial Hypertension 4
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 8.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Medicine Products: